By The FDA is providing this communication to increase awareness of recent updates to the product labeling of capecitabine and fluorouracil (5-FU) related to risks associated with dihydropyrimidine dehydrogenase (DPD) deficiency.
Top News
- Anesthetic and Analgesic Drug Products Advisory Committee Roster
- Drug Safety and Risk Management Advisory Committee Roster
- FDA approves penpulimab-kcqx for non-keratinizing nasopharyngeal carcinoma
- Pain and Arthritis Products Containing Hidden Ingredients
- Painflex Forte may be harmful due to hidden drug ingredients
- Max Chemical Inc. – 682037 – 06/20/2024
- Her Neighbor of 15 Years Turned Out to Be Family—thanks to DNA
- 6 Things to Do in Ennis, Texas—From Bluebonnet Trails to a Railroad Museum
- ATM Glitch is Causing Chase to Sue Over 1,000 People—Were You Part of It?
- She Rescued a Dog on a Mountain—And He Rescued Her Family, Too
- April 21 to April 27 Horoscope Forecast: Your Zodiac Sign’s Week
- More Money Found: 11 Refunds and Credits You Can Get on Common Expenses
- NB Industry accelerates global shift despite US overtures to China
- Delta Electronics sees India gains amid global tariff war, eyes local expansion
- CloudMile highlights mixed progress in Southeast Asia’s AI development
- Router maker TP-Link faces US criminal antitrust investigation
- Intel to continue boosting in-house chip production, braces for tariff impacts
- Intel Foundry sales rise, losses narrow as company unveils major cost-cutting plan
